+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Respiratory Syncytial Virus (RSV) Therapeutics - Global Market Trajectory & Analytics

  • ID: 5310780
  • Report
  • April 2021
  • Region: Global
  • 176 pages
  • Global Industry Analysts, Inc
Global Respiratory Syncytial Virus (RSV) Therapeutics Market to Reach $2.4 Billion by 2027

Amid the COVID-19 crisis, the global market for Respiratory Syncytial Virus (RSV) Therapeutics estimated at US$1.2 Billion in the year 2020, is projected to reach a revised size of US$2.4 Billion by 2027, growing at a CAGR of 10.4% over the analysis period 2020-2027. Palivizumab, one of the segments analyzed in the report, is projected to record a 11.4% CAGR and reach US$1.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Ribavirin segment is readjusted to a revised 8.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $360.6 Million, While China is Forecast to Grow at 9.7% CAGR

The Respiratory Syncytial Virus (RSV) Therapeutics market in the U.S. is estimated at US$360.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$416.3 Million by the year 2027 trailing a CAGR of 9.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.5% and 8.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Other Drug Types Segment to Record 7.5% CAGR

In the global Other Drug Types segment, USA, Canada, Japan, China and Europe will drive the 7.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$99.7 Million in the year 2020 will reach a projected size of US$166 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$279.6 Million by the year 2027.

Select Competitors (Total 41 Featured):
  • AbbVie, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • ReViral Ltd.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Palivizumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Palivizumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Palivizumab by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Ribavirin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Ribavirin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Ribavirin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 16: World Current & Future Analysis for InjecTable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for InjecTable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for InjecTable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 19: World Current & Future Analysis for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 20: World Historic Review for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 21: World 15-Year Perspective for Other Dosage Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 22: USA Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 23: USA Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 24: USA 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Palivizumab, Ribavirin and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 25: USA Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: USA Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 27: USA 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Percentage Breakdown of Value Sales for Oral, InjecTable and Other Dosage Forms for the Years 2012, 2020 & 2027
  • CANADA
  • Table 28: Canada Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 29: Canada Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 30: Canada 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Palivizumab, Ribavirin and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 31: Canada Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: Canada Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 33: Canada 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Percentage Breakdown of Value Sales for Oral, InjecTable and Other Dosage Forms for the Years 2012, 2020 & 2027
  • JAPAN
  • Table 34: Japan Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 35: Japan Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 36: Japan 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Palivizumab, Ribavirin and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 37: Japan Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 38: Japan Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 39: Japan 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Percentage Breakdown of Value Sales for Oral, InjecTable and Other Dosage Forms for the Years 2012, 2020 & 2027
  • CHINA
  • Table 40: China Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 41: China Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 42: China 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Palivizumab, Ribavirin and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 43: China Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 44: China Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 45: China 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Percentage Breakdown of Value Sales for Oral, InjecTable and Other Dosage Forms for the Years 2012, 2020 & 2027
  • EUROPE
  • Table 46: Europe Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 47: Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 48: Europe 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 49: Europe Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 50: Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 51: Europe 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Palivizumab, Ribavirin and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 52: Europe Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 53: Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 54: Europe 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Percentage Breakdown of Value Sales for Oral, InjecTable and Other Dosage Forms for the Years 2012, 2020 & 2027
  • FRANCE
  • Table 55: France Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 56: France Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 57: France 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Palivizumab, Ribavirin and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 58: France Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 59: France Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 60: France 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Percentage Breakdown of Value Sales for Oral, InjecTable and Other Dosage Forms for the Years 2012, 2020 & 2027
  • GERMANY
  • Table 61: Germany Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 62: Germany Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 63: Germany 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Palivizumab, Ribavirin and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 64: Germany Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 65: Germany Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 66: Germany 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Percentage Breakdown of Value Sales for Oral, InjecTable and Other Dosage Forms for the Years 2012, 2020 & 2027
  • ITALY
  • Table 67: Italy Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 68: Italy Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 69: Italy 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Palivizumab, Ribavirin and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 70: Italy Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 71: Italy Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 72: Italy 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Percentage Breakdown of Value Sales for Oral, InjecTable and Other Dosage Forms for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
  • Table 73: UK Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 74: UK Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 75: UK 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Palivizumab, Ribavirin and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 76: UK Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 77: UK Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 78: UK 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Percentage Breakdown of Value Sales for Oral, InjecTable and Other Dosage Forms for the Years 2012, 2020 & 2027
  • REST OF EUROPE
  • Table 79: Rest of Europe Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 80: Rest of Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 81: Rest of Europe 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Palivizumab, Ribavirin and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 82: Rest of Europe Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 83: Rest of Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 84: Rest of Europe 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Percentage Breakdown of Value Sales for Oral, InjecTable and Other Dosage Forms for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
  • Table 85: Asia-Pacific Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 86: Asia-Pacific Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 87: Asia-Pacific 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Palivizumab, Ribavirin and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 88: Asia-Pacific Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 89: Asia-Pacific Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 90: Asia-Pacific 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Percentage Breakdown of Value Sales for Oral, InjecTable and Other Dosage Forms for the Years 2012, 2020 & 2027
  • REST OF WORLD
  • Table 91: Rest of World Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 92: Rest of World Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Palivizumab, Ribavirin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 93: Rest of World 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Palivizumab, Ribavirin and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 94: Rest of World Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 95: Rest of World Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Oral, InjecTable and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 96: Rest of World 15-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Dosage Form - Percentage Breakdown of Value Sales for Oral, InjecTable and Other Dosage Forms for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 41
Note: Product cover images may vary from those shown
Adroll
adroll